Product Description
The EyeGate II Delivery System and EGP-437 combination product, is being evaluated for the treatment of pain and inflammation in patients having undergone cataract surgery with implantation of a monofocal posterior chamber IOL (intraocular lens).
Mechanisms of Action: GR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Ocular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kiora Pharmaceuticals
Company Location: WALTHAM MA 02452
Company CEO: Brian M. Strem
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Uveitis, Anterior|Iridocyclitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| EGP-437-006 | P3 |
Completed |
Iridocyclitis|Uveitis, Anterior |
2018-04-20 |
18% |
2019-03-22 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/31/2020 |
News Article |
EyeGate Pharma Announces Positive Topline Data in Follow-on Dry Eye Pilot Study |
|
03/01/2020 |
PubMed |
Iontophoretic Dexamethasone Phosphate Compared to Topical Prednisolone Acetate 1% for Noninfectious Anterior Segment Uveitis. |
|
03/01/2020 |
PubMed |
Ophthalmic Drug Delivery Using Iontophoresis: Recent Clinical Applications. |
|
01/03/2020 |
News Article |
EyeGate Announces Completion of $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules |
|
12/31/2019 |
News Article |
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules |
|
12/17/2019 |
News Article |
EyeGate Pharma Receives $1.9 Million from Exercised Warrants |